In 2007-2014, Glycemic Control Plateaued in Diabetes Patients

Share this content:
In 2007-2014, Glycemic Control Plateaued in Diabetes Patients
In 2007-2014, Glycemic Control Plateaued in Diabetes Patients

WEDNESDAY, Nov. 15, 2017 (HealthDay News) -- Despite increases in HbA1c testing and awareness, glycemic control seems to have plateaued among patients with diabetes between 2007 and 2014, according to a research letter published online Nov. 14 in the Journal of the American Medical Association.

Saeid Shahraz, M.D., Ph.D., from Brandeis University in Waltham, Massachusetts, and colleagues examined recent trends in glycemic control and patient awareness of HbA1c test results and targets using data from four survey periods of the National Health and Nutrition Examination Survey (2007-2008, 2009-2010, 2011-2012, and 2013-2014).

The researchers found that glycemic control did not change between 2007-2008 and 2013-2014 overall or in any subgroup. Over the study period, a higher proportion of patients with diabetes reported having an HbA1c test within the past year (55.1 percent in 2007-2008 versus 77.78 percent in 2013-2014). There was a similar change in all subgroups. There was also a significant increase in the percent of patients reporting being aware of their past-year HbA1c result (52.32 percent in 2007-2008 versus 74.31 percent in 2013-2014). This change was statistically significant in all subgroups except participants aged 20 to 44 years.

"The improvement in glycemic control between 1998 and 2010 among patients with diabetes appears to have plateaued during 2007-2014," conclude the authors.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell Lymphomas

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell ...

Second study shows benefit in relapsed or refractory B-cell lymphoma, follicular lymphoma

ASH: AAVD Beats ABVD for Advanced Hodgkin's Lymphoma

ASH: A+AVD Beats ABVD for Advanced Hodgkin's Lymphoma

Lower combined risk of progression, death, or noncomplete response with A+AVD

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia A

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia ...

Factor VIII gene transfer tied to sustained normalization of factor VIII activity levels

is free, fast, and customized just for you!

Already a member?

Sign In Now »